Anthropic PBC has launched Claude Science, a new artificial intelligence platform that promises to streamline scientific research by automating routine laboratory work and reducing the burden of repetitive data processing tasks. The system, which became available on June 30 to the company's subscription users, represents a significant push by the San Francisco-based AI developer to establish itself as an indispensable tool across the life sciences sector.
The platform consolidates access to more than 60 scientific databases, allowing researchers to interact with these resources through simple conversational language rather than managing complex queries across multiple disparate systems. This integration addresses a persistent pain point in modern research: the fragmented nature of scientific information sources and the time scientists spend navigating between platforms. By enabling multistep tasks to be executed through a single interface, Claude Science aims to liberate researchers from administrative overhead and redirect their intellectual effort toward hypothesis development and experimental design.
Claude Science can perform sophisticated functions within its scope, including protein structure prediction and analysis across biology and chemistry disciplines. The platform operates on existing Claude models, notably the Opus 4.8 iteration released in May, ensuring compatibility with Anthropic's established infrastructure. Critically, the outputs generated by Claude Science include traceable metadata and methodology documentation, allowing scientists to verify accuracy and understand the computational steps underlying analytical conclusions. Generated images similarly contain embedded information about their creation process, addressing transparency concerns that plague AI-assisted research.
Anthropologic simultaneously announced an internal pivot toward pharmaceutical development, establishing its own preclinical drug discovery operations. Eric Kauderer-Abrams, heading the company's life sciences division, indicated that Anthropic would target therapeutic areas that conventional pharmaceutical companies have deemed commercially unattractive or scientifically unfeasible. This strategic move positions the company not merely as a software vendor but as a participant in the pharmaceutical ecosystem itself, potentially creating proprietary advantages in understanding which AI capabilities translate into viable medicines.
The timing of this announcement underscores the intensifying competition between AI leaders to dominate professional services sectors. Both Anthropic and rival OpenAI have spent the past eighteen months developing specialised AI applications targeting finance, law, healthcare, and scientific research. These efforts reflect a deliberate strategy to justify the staggering valuations these companies command—Anthropic is currently valued at US$965 billion (RM3.94 trillion)—and to establish themselves as essential infrastructure rather than novelty tools. Anthropic is reportedly targeting an initial public offering by autumn, making such tangible product launches crucial for demonstrating revenue potential and market disruption.
Anthropologic's recent product releases have triggered significant market anxiety about technological obsolescence. In February, when the company introduced Claude Cowork for automating legal tasks including contract review and legal memoranda generation, equity markets responded with a US$1 trillion (RM4.08 trillion) sell-off as investors grappled with implications for professional services employment. Claude Science carries similar potential to reshape research institutions, potentially reducing demand for certain scientific support roles and accelerating the pace of drug discovery timelines.
The announcement occurred at a San Francisco event featuring Dario Amodei, Anthropic's chief executive, alongside prominent figures from the pharmaceutical industry. Vas Narasimhan, chief executive of Novartis AG and an Anthropic board member, and Chris Boerner, CEO of Bristol-Myers Squibb Co, participated in discussions about AI's role in drug development. Their involvement signals heavyweight endorsement and suggests preliminary integration between Anthropic's systems and major pharmaceutical workflows.
Dario Amodei articulated an expectation that within twelve months, tangible pharmaceutical achievements would emerge from AI-assisted target discovery. This assertion reflects recognition that the AI industry's credibility increasingly depends on delivering measurable outcomes rather than theoretical capabilities. The sector has faced mounting scepticism regarding whether its proclamations will translate into practical results that benefit patients and advance public health.
Narasimhan emphasised that appropriate regulatory frameworks must accompany technological advancement. His warning that regulatory progress should not await crisis intervention reflects broader industry concern about the gap between technological capability and governance infrastructure. For Southeast Asian jurisdictions including Malaysia, which are developing AI regulation frameworks, this intervention by major pharmaceutical leaders reinforces the necessity of proactive rather than reactive policy development.
The Claude Science release emerges within a constrained operating environment for Anthropic. Merely two weeks earlier, the company had disabled access to its most advanced models—Fable 5 and Mythos 5—following a Trump administration directive restricting technology access to foreign nationals. By June 26, Anthropic obtained approval to restore partial access to Mythos 5 after addressing national security concerns, though no announcement has addressed Fable 5 restrictions. This regulatory environment in the United States will likely establish precedents affecting how Southeast Asian governments approach AI governance and international technology access policies.
For Malaysian scientific institutions and pharmaceutical companies, Claude Science presents both opportunity and competitive pressure. Early adoption could accelerate research productivity and drug discovery timelines, positioning Malaysian institutions at the frontier of biotechnology innovation. Conversely, the efficiency gains offered by such platforms may reduce hiring demand for junior research scientists and support staff, requiring workforce adjustments in research-intensive sectors across the region. The platform's integration with existing databases and requirement for paid subscriptions also raises questions about research equity in developing economies.
